Daix
(France),
Long Island City (New York, United States),
May 23, 2022
– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the development of small molecules administered orally for the treatment of patients with non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs, announces today that its management team will participate in two investor conferences during the months of May and June 2022.
The event details are as follows:
|
Conference #1: |
” HC Wainwright Annual Global Life Sciences Conference » |
|
Event type : | Investor meetings and question-and-answer session (Q&A) |
|
Date of Q&A: | Tuesday, May 24 at 11:00-11:30 a.m. (Eastern time) / 5:00-5:30 p.m. (Paris time) |
|
Format: | Hybrid event |
|
Conference #2: |
« Jefferies 2022 Global Healthcare Conference » |
|
Event type : | Investor meetings and question-and-answer session (Q&A) |
|
Date of Q&A: | Thursday, June 9, 2022 at 11:00 a.m. – 11:25 a.m. (Eastern time) / 5:00 p.m. – 5:25 p.m. (Paris time) |
|
Format: | physical event |
The link to access the event
« Jefferies 2022 Global Healthcare Conference
»
will be available on Inventiva’s website in the ”
Investors
–
Investor presentations
“.
About Inventiva
Inventiva is a biopharmaceutical company specializing in the research and development of orally administered small molecules for the treatment of patients with NASH and other diseases with significant unmet medical needs. The Company has significant experience and expertise in the development of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Lanifibranor, Inventiva’s most advanced drug candidate, is currently being evaluated in the pivotal Phase III NATiV3 clinical study for the treatment of adult patients with NASH, a common and progressive chronic liver disease, for which it there is currently no approved treatment.
The Company entered into a strategic partnership with AbbVie in the field of autoimmune diseases which led to the discovery of the drug candidate cedirogant (ABBV-157), an orally administered RORγ inverse agonist whose efficacy in adult patients with Moderate to severe plaque psoriasis is being evaluated in a Phase IIb clinical study conducted by AbbVie. Inventiva’s portfolio also includes odiparcil, a drug candidate for the treatment of adult patients with mucopolysaccharidosis (MPS) type VI. As part of its decision to focus its clinical efforts on the development of lanifibranor, Inventiva has suspended its clinical efforts with odiparcil and is reviewing all available options to optimize its development. Inventiva is in the process of selecting a drug candidate in oncology as part of its program dedicated to the Hippo signaling pathway.
The Company has a scientific team of approximately 80 people with strong expertise in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as in clinical development. Inventiva has a chemical library of around 240,000 molecules, of which around 60% are exclusive to the Company, as well as its own laboratories and equipment.
Inventiva is listed on compartment C of the regulated market of Euronext Paris (Euronext Paris: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (symbol: IVA).
www.inventivapharma.com
.
contacts
Enclosed
Inventiva-PR-Results-AG-2022-FR-20.05.2022